AN2 Therapeutics Files 8-K on Financials
Ticker: ANTX · Form: 8-K · Filed: Mar 28, 2024 · CIK: 1880438
Sentiment: neutral
Topics: financial-reporting, operations
Related Tickers: ANTX
TL;DR
AN2 Therapeutics filed an 8-K, expect financial updates soon.
AI Summary
On March 28, 2024, AN2 Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as financial statements and exhibits. No specific financial figures or operational updates were detailed in the provided excerpt.
Why It Matters
This filing indicates AN2 Therapeutics is providing updates on its financial condition and operations, which is crucial for investors to assess the company's performance and outlook.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of financial information and does not contain any immediate negative news or significant operational changes.
Key Players & Entities
- AN2 Therapeutics, Inc. (company) — Registrant
- 0000950170-24-038055 (filing_id) — Accession Number
- March 28, 2024 (date) — Date of Report
- 1800 El Camino Real, Suite D (address) — Principal Executive Offices
- Menlo Park, California (location) — Principal Executive Offices
- 94027 (zip_code) — Principal Executive Offices
- 650 331-9090 (phone_number) — Registrant's Telephone Number
FAQ
What specific financial results are being reported by AN2 Therapeutics in this 8-K?
The provided excerpt of the 8-K filing indicates it pertains to 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits,' but it does not detail specific financial figures.
When was this 8-K filing submitted to the SEC?
The filing was submitted on March 28, 2024.
What is the principal business address of AN2 Therapeutics, Inc.?
The principal executive offices are located at 1800 El Camino Real, Suite D, Menlo Park, California, 94027.
What is the Commission File Number for AN2 Therapeutics, Inc.?
The Commission File Number for AN2 Therapeutics, Inc. is 001-41331.
What is the SIC code for AN2 Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for AN2 Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 512 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2024-03-28 16:15:15
Filing Documents
- antx-20240328.htm (8-K) — 39KB
- antx-ex99_1.htm (EX-99.1) — 136KB
- 0000950170-24-038055.txt ( ) — 300KB
- antx-20240328.xsd (EX-101.SCH) — 25KB
- antx-20240328_htm.xml (XML) — 5KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On March 28, 2024, AN2 Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2023. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. All of the information furnished in this Item 2.02 and Item 9.01 (including Exhibit 99.1) shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as shall be expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. Exhibit Number Description 99.1 Press Release of AN2 Therapeutics Inc. dated March 28, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AN2 Therapeutics, Inc. Date: March 28, 2024 By: /s/ Eric Easom Eric Easom Chief Executive Officer and Director (Principal Executive Officer)